Charles River Laboratories International (CRL) Hisse Fiyat
Charles River Laboratories International Fiyat
Charles River Laboratories International, son 19 yılda gelirini yıllık %7,3 artırarak 4,02 Md USD seviyesine taşıdı. Hisse başına kâr, son 17 yılda yıllık %13,1 geriledi. Charles River Laboratories International için net marj, %-3,6 ile birkaç yıl önceki %11,0 seviyesine göre geriledi. Charles River Laboratories International için 12 aylık konsensüs fiyat hedefi 273,00 USD; bu, hissenin bugünkü fiyatının yaklaşık %12,2 altında bir seviyeye denk geliyor. 23 analistten 17 tanesi hisse için alım öneriyor — genel konsensüs: Al.
Charles River Laboratories International hisse senedi fiyatı
Charles River Laboratories International iş modeli ve hisse analizi
Charles River Laboratories International hakkında sık sorulan sorular
The business model of Charles River Laboratories International Inc primarily revolves around providing research and development (R&D) solutions and services to the pharmaceutical, biotechnology, and medical device companies. As a leading contract research organization (CRO), the company offers a wide range of preclinical and clinical laboratory services, including safety assessment, discovery support, manufacturing support, and laboratory animal research services. Charles River Laboratories operates on a fee-for-service basis, collaborating with its clients to accelerate drug discovery, development, and commercialization processes. With a focus on quality, reliability, and scientific expertise, the company aims to support its clients in advancing their scientific research and achieving their business goals.
Charles River Laboratories International Inc is primarily active in the life sciences industry.
Some of the main competitors of Charles River Laboratories International Inc in the market include Covance Inc., Envigo, PPD, Eurofins Scientific, and LabCorp.
Charles River Laboratories International Inc is a renowned company in the field of preclinical and clinical laboratory services. Founded in 1947, Charles River has built a strong reputation as a trusted provider of comprehensive research support. With a focus on helping pharmaceutical and biotechnology companies bring new drugs to market, they offer a wide range of services including drug discovery, safety assessment, and manufacturing support to clients worldwide. The company's expertise in advanced animal models, laboratory sciences, and support services has propelled it to the forefront of the life sciences industry. Today, Charles River Laboratories continues to play a vital role in advancing much-needed medical therapies.
Charles River Laboratories International Inc has achieved several significant milestones. It has consistently demonstrated strong financial performance, delivering consistent revenue growth and expanding its global footprint. The company has successfully completed strategic acquisitions, enabling it to enhance its capabilities and expand its service offerings. Charles River Laboratories International Inc has also received notable recognition, including being named one of the World's Most Ethical Companies for several consecutive years. Moreover, the company has been at the forefront of scientific advancements, collaborating with global pharmaceutical and biotechnology companies to develop innovative solutions that improve drug discovery and development processes.
Charles River Laboratories International Inc is primarily present in the following countries and regions: United States, Canada, Europe, Asia Pacific, and Latin America.
Charles River Laboratories International Inc represents various values and corporate philosophies. The company is committed to their mission of improving the lives of people and animals through innovative research and development. They aim to maintain the highest standards of scientific integrity, ethical conduct, and regulatory compliance. Charles River Laboratories prioritizes collaboration and partnership with their clients to provide comprehensive solutions and exceptional service. With a focus on quality, efficiency, and expertise, they strive to consistently deliver reliable and innovative scientific services and products. Through their dedication to responsible and sustainable practices, Charles River Laboratories aims to make a positive impact on society and the environment.
Analistler şu anda Charles River Laboratories International hissesi için ortalama 267,60 USD hedef fiyat belirliyor (medyan: 273,00 USD); bu, son fiyata göre -13,9 % anlamına gelir. Konsensüs 23 analist notuna dayanır.
Charles River Laboratories International Analist Fiyat Hedefleri 2026
23 analist şu anda Charles River Laboratories International hissesini değerlendiriyor: 17 al, 6 tut, 0 sat öneriyor. 2026 için analistler Charles River Laboratories International şirketinin 3,91 Md USD gelir ve 11,42 USD hisse başına kâr üretmesini bekliyor.
Charles River Laboratories International Analist Fiyat Hedefleri 2026
Güncel döviz kuruyla Charles River Laboratories International hissesi 276,24 EUR (310,77 USD) seviyesindedir.
Charles River Laboratories International hissesi (CRL) 6 borsada işlem görür, bunlar arasında: NYSE (CRL), SIX (Zürich) (RV6.SW), XETRA (RV6.DE), Frankfurt (RV6.F), München (RV6.MU), Düsseldorf (RV6.DU).
Charles River Laboratories International Inc is a global leader in the field of life sciences, offering its customers a wide range of products and services. The company's business model is based on three main areas: research and development, preclinical services, and bioproducts. Research and Development: Charles River Laboratories offers a variety of services to support its customers in the development of new products. These include chemical and pharmacological screening systems, study design and planning, cell and tissue banking, genotoxicology, protein and antibody production, and much more. Charles River Laboratories has a comprehensive range of scientific and technical capabilities to assist its customers in the development of new drugs, biotechnology products, and medical devices. Preclinical Services: The company provides its customers with a wide range of preclinical services to test the safety and efficacy of products. These services include toxicology, pathology, pharmacology, bioanalytics, and clinical diagnostics. Charles River Laboratories has several preclinical research facilities worldwide and can support customers in the validation of new therapies and products. Bioproducts: Charles River Laboratories produces a variety of bioproducts for research and development, including cell lines, antibodies, nucleic acids, and proteins. The company also offers specialized services such as genetic manipulation and custom modification of cell lines to achieve specific research goals. The company focuses on customer loyalty and has earned the trust of customers by offering high-quality products and services. Charles River Laboratories has a global presence with facilities in North America, Europe, and Asia, and can serve customers worldwide. The company also maintains a strong partnership with the scientific community by supporting research initiatives and public health measures. Charles River Laboratories is committed to offering its customers a comprehensive range of services to meet their needs in the field of life sciences. The company is dedicated to continuously improving its research and development and introducing new services and products to meet the ever-changing needs of customers.
beklenen'nin Charles River Laboratories International hasılatı 3,91 Md USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin Charles River Laboratories International karı 561,96 M USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
Charles River Laboratories International'nin Fiyat/Kazanç (F/K) oranı şu anda 27,22'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Charles River Laboratories International hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
Charles River Laboratories International'nin Fiyat/Satış (F/S) oranı şu anda 3,91'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Charles River Laboratories International hisse senedinin değerleme metriği olarak hizmet eder.
Charles River Laboratories International'nin Eulerpool Kalite Puanı 3/10'dur.
Charles River Laboratories International'nin ISIN'i US1598641074'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
Charles River Laboratories International'nin WKN'i 939391'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
Charles River Laboratories International'nin ticker'ı CRL'dir. Ticker sembolü, Charles River Laboratories International hisseleri borsada işlem görmek için kullanılır.
Charles River Laboratories International Hissesi
Charles River Laboratories International Emsaller Grubu
Charles River Laboratories International Ticker
Charles River Laboratories International FIGI
Charles River Laboratories International'nin tüm temel göstergeleri ve derinlemesine analizi
Charles River Laboratories International hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Charles River Laboratories International şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: